Title |
Managing drug resistance in cancer: lessons from HIV therapy
|
---|---|
Published in |
Nature Reviews Cancer, June 2012
|
DOI | 10.1038/nrc3297 |
Pubmed ID | |
Authors |
Christoph Bock, Thomas Lengauer |
Abstract |
Drug resistance is a common cause of treatment failure for HIV infection and cancer. The high mutation rate of HIV leads to genetic heterogeneity among viral populations and provides the seed from which drug-resistant clones emerge in response to therapy. Similarly, most cancers are characterized by extensive genetic, epigenetic, transcriptional and cellular diversity, and drug-resistant cancer cells outgrow their non-resistant peers in a process of somatic evolution. Patient-specific combination of antiviral drugs has emerged as a powerful approach for treating drug-resistant HIV infection, using genotype-based predictions to identify the best matched combination therapy among several hundred possible combinations of HIV drugs. In this Opinion article, we argue that HIV therapy provides a 'blueprint' for designing and validating patient-specific combination therapies in cancer. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 80% |
Austria | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 3 | 60% |
Members of the public | 2 | 40% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 6 | 2% |
Austria | 3 | 1% |
Netherlands | 2 | <1% |
United Kingdom | 2 | <1% |
Korea, Republic of | 1 | <1% |
France | 1 | <1% |
Germany | 1 | <1% |
Canada | 1 | <1% |
Singapore | 1 | <1% |
Other | 5 | 2% |
Unknown | 238 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 74 | 28% |
Student > Ph. D. Student | 73 | 28% |
Student > Master | 16 | 6% |
Other | 15 | 6% |
Student > Bachelor | 13 | 5% |
Other | 40 | 15% |
Unknown | 30 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 99 | 38% |
Biochemistry, Genetics and Molecular Biology | 48 | 18% |
Medicine and Dentistry | 26 | 10% |
Engineering | 15 | 6% |
Chemistry | 14 | 5% |
Other | 28 | 11% |
Unknown | 31 | 12% |